Noah Chelliah, MD
Cardiovascular Disease · Grand Forks, NDNPI 1952485740
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $100,600 of the $115,215 with a category attached, or 87.3%. Abbott accounts for 99.5% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $48,366 and has fallen 93.2% since, to $3,307 in 2025. Among cardiovascular disease clinicians in ND with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 461 payments — averaging $249.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$115K
- Johnson & Johnson$252
- Merck$53
- E.r. Squibb & Sons, L.L.C.$52
- Lexicon Pharmaceuticals, Inc.$51
- AstraZeneca$49
- plus $177 from 9 others
What the payments were for
- Consulting fees$100,60087%
- Travel & lodging$5,0384%
- Food & beverage$9,5788%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 419 | $114,582 |
| Johnson & Johnson | 18 | $252 |
| Merck | 3 | $53 |
| E.r. Squibb & Sons, L.L.C. | 4 | $52 |
| Lexicon Pharmaceuticals, Inc. | 3 | $51 |
| AstraZeneca | 3 | $49 |
| Bayer | 2 | $32 |
| Itamar Medical Inc | 1 | $30 |
| Novartis | 2 | $24 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Bridgebio Pharma, Inc. | 1 | $17 |
| Novo Nordisk | 1 | $15 |
| Boehringer Ingelheim | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Vifor Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Accent Pacemaker$25,194
- Allure CRT Pacemaker$16,076
- Confirm Rx$15,396
- Quartet CRT Lead$12,992
- Optisure Defibrillation ICD Lead$11,136
- Quadra Allure MP RF CRT Pacemkr$7,424
- Allure Quadra RF CRT Pacemaker$5,060
- ALLURE$4,000
- Assurity Pacemaker$2,778
- Quadra Assura CRT Defibrillator$2,010
- Cardiovascular- Research only$1,469
- ACCENT$1,379
- AVEIR$497
- GALLANT$103
How this compares
$115,215 in reported general payments places this provider in the 95th percentile of 35 cardiovascular disease providers in North Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 113 | $68,337 |
| EntrestoSacubitril/Valsartan | 47 | $39,987 |
| EliquisApixaban | 26 | $27,438 |
| FarxigaDapagliflozin Propanediol | 13 | $10,183 |
| Metoprolol Succinate | 106 | $1,431 |
| Digoxin | 74 | $1,360 |
| Diltiazem 24hr Er (La)Diltiazem Hcl | 16 | $1,174 |
| Verapamil ErVerapamil Hcl | 18 | $969 |
| ClopidogrelClopidogrel Bisulfate | 30 | $475 |
| Clonidine Hcl | 41 | $423 |
| Carvedilol | 53 | $363 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 30 | $361 |
| Ezetimibe-SimvastatinEzetimibe/Simvastatin | 12 | $339 |
| Spironolactone | 47 | $332 |
| Losartan Potassium | 32 | $287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $252 | $68,337113 claims |
| NovartisEntresto | $24 | $39,98747 claims |
| AstraZenecaFarxiga | $49 | $10,18313 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 35 cardiovascular disease providers in North Dakota.
Other cardiovascular disease in Grand Forks
- Hussain BasrawalaGrand Forks$40K
- Mikhail KirnusGrand Forks$16K
- Rabeea AboufakherGrand Forks$14K
- Mohamed ChebacloGrand Forks$7K
- Puvanalingam AyyaduraiGrand Forks$3K
- Abdelhamid AhmedGrand Forks$17
- Beng Loong Isaac TeaMinot$42K
- Thomas HaldisFargo$37K
- Matthew GlogozaFargo$36K
- Timothy PansegrauBismarck$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.